Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 11/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032523 | 0.76 | PPARA (0.66) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| SCHEMBL23867614 | 0.76 | PPARG (0.47) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| SCHEMBL27393596 | 0.75 | PPARG (0.46) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| SCHEMBL11383504 | 0.75 | PPARG (0.46) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| SCHEMBL247466 | 0.74 | PPARA (0.68) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| SCHEMBL1618680 | 0.73 | PPARG (0.44) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL7026339 | 0.72 | PPARA (0.66) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| SCHEMBL13072375 | 0.72 | PPARA (0.50) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8889149 | 0.72 | PPARA (0.66) | PPARGPPARACYP2C19MEN1CYP1A2 | |
| SCHEMBL11127080 | 0.72 | PPARA (0.50) | PPARGPPARACYP2C19MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099419-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | disclosed |
| US-12201603-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11617733-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-04 | — | — | US | disclosed |
| US-20210169842-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-10940134-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20200093781-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-03-26 | — | — | US | disclosed |
| US-20190111019-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-04-18 | — | — | US | disclosed |
| US-10201520-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20180116995-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20150112079-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| US-8962868-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| EP-2460801-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-20140073676-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8614340-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICALS CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| US-20130324577-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-05 | — | — | US | disclosed |
| EP-2669279-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-2653468-A1 | Bicyclic Compound and Use Thereof for Medical Purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2460801-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-20250099419-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-20180116995-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-20200093781-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-11617733-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-10201520-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-20190111019-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-10940134-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-20130324577-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | PDE3A, PDE10A, PDE2A | PPARG 323/4885HSD11B1 227/4885PPARA 480/4885 |
| US-20210169842-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-12201603-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-20150112079-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-20140073676-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | PPARG 267/4885HSD11B1 154/4885PPARA 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.